Dr. Stephen Hill Named to PhRMA Board of Directors
Stephen Hill
President and CEO of Solvay Pharmaceuticals to Serve Three-Year Term
Marietta, Ga. (May 5, 2008) - Solvay Pharmaceuticals, Inc. announced today that Stephen Hill, B.M., B.Ch., M.A., F.R.C.S., president and chief executive officer, has been named to the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). Hill was elected to serve a three-year term through April 2011.
PhRMA represents the country’s leading pharmaceutical research and biotechnology companies, which are devoted to inventing medicines that allow patients to live longer, healthier, and more productive lives.
“I look forward to collaborating with my colleagues on the Board of PhRMA to further the organization’s mission, address issues facing Solvay Pharmaceuticals and the entire industry and most importantly, help improve the lives of the patients we serve,” said Hill.
“PhRMA looks forward to the expertise and leadership Dr. Hill brings to the Board as we continue to advocate for public policies that encourage the discovery of life-saving and life enhancing new medicines for patients,” said Billy Tauzin, president and CEO of PhRMA.
Before joining Solvay, Hill most recently served as president and CEO of biotechnology firm ArQule, Inc. since 1999. Before joining ArQule, Hill was the Head of Global Drug Development at F. Hoffmann-La Roche Ltd. from 1997-1999. He joined Roche in 1989 as Medical Adviser to Roche Products in the United Kingdom and held several senior positions there that included U.K. Medical Director and Head of International Drug Regulatory Affairs at Roche headquarters in Basel, Switzerland. Hill is a Fellow of the Royal College of Surgeons of England and holds his scientific and medical degrees from St. Catherine's College at Oxford University.
About Solvay Pharmaceuticals, Inc. Solvay Pharmaceuticals, Inc., of Marietta, Georgia is the U.S. subsidiary of Solvay Pharmaceuticals. For more information, visit www.solvaypharmaceuticals-us.com.
Solvay Pharmaceuticals is a research driven group of companies that constitute the global pharmaceutical business of the Solvay Group. The company seeks to fulfill carefully selected, unmet medical needs in the therapeutic areas of neuroscience, cardio-metabolic, influenza vaccines, gastroenterology, and men’s and women’s health. Its 2007 sales were EUR 2.6 billion and it employs more than 9,000 people worldwide. For more information, visit www.solvaypharmaceuticals.com.
SOLVAY is an international chemical and pharmaceutical Group with headquarters in Brussels. It employs more than 28,000 people in 50 countries. In 2007, its consolidated sales amounted to EUR 9.6 billion, generated by its three sectors of activity: Chemicals, Plastics and Pharmaceuticals. Solvay (NYSE Euronext: SOLB.BE - Bloomberg: SOLB.BB - Reuters: SOLBt.BR) is listed on the NYSE Euronext stock exchange in Brussels. Details are available at www.solvay.com
